JPWO2020102646A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102646A5 JPWO2020102646A5 JP2021526441A JP2021526441A JPWO2020102646A5 JP WO2020102646 A5 JPWO2020102646 A5 JP WO2020102646A5 JP 2021526441 A JP2021526441 A JP 2021526441A JP 2021526441 A JP2021526441 A JP 2021526441A JP WO2020102646 A5 JPWO2020102646 A5 JP WO2020102646A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- cancer
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- -1 C 1-8 alkylC(O)— Chemical group 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 3
- 229960005305 adenosine Drugs 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 102100021723 Arginase-1 Human genes 0.000 claims 2
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 claims 2
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000004452 Arginase Human genes 0.000 claims 1
- 108700024123 Arginases Proteins 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000709 aorta Anatomy 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000024662 testicular seminoma Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768284P | 2018-11-16 | 2018-11-16 | |
| US62/768,284 | 2018-11-16 | ||
| PCT/US2019/061657 WO2020102646A2 (en) | 2018-11-16 | 2019-11-15 | Inhibitors of arg1 and/or arg2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507474A JP2022507474A (ja) | 2022-01-18 |
| JPWO2020102646A5 true JPWO2020102646A5 (ru) | 2022-11-24 |
| JP7461350B2 JP7461350B2 (ja) | 2024-04-03 |
Family
ID=70731928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526441A Active JP7461350B2 (ja) | 2018-11-16 | 2019-11-15 | Ａｒｇ１及び／又はａｒｇ２の阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220016143A1 (ru) |
| EP (1) | EP3880685A4 (ru) |
| JP (1) | JP7461350B2 (ru) |
| KR (1) | KR20210108954A (ru) |
| CN (1) | CN113382998A (ru) |
| AR (1) | AR117102A1 (ru) |
| AU (1) | AU2019379808C1 (ru) |
| CA (1) | CA3120196A1 (ru) |
| TW (1) | TWI828800B (ru) |
| UY (1) | UY38476A (ru) |
| WO (1) | WO2020102646A2 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115298165A (zh) | 2020-03-19 | 2022-11-04 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| PE20231078A1 (es) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| KR20230026312A (ko) | 2020-06-17 | 2023-02-24 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 억제제의 결정형 및 이의 용도 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| TW202313603A (zh) | 2021-05-21 | 2023-04-01 | 美商阿克思生物科學有限公司 | Axl抑制劑化合物 |
| EP4341261A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl compounds |
| CA3236553A1 (en) | 2021-10-29 | 2023-05-04 | Joel Worley BEATTY | Inhibitors of hif-2alpha and methods of use thereof |
| WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024059142A1 (en) | 2022-09-14 | 2024-03-21 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| WO2024086718A1 (en) | 2022-10-20 | 2024-04-25 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101854820B1 (ko) * | 2009-09-25 | 2018-05-04 | 샤이어 오펀 테라피즈 게엠베하 | 신규한 ｎｐｒ－ｂ 길항제 |
| KR101931822B1 (ko) * | 2010-04-22 | 2018-12-24 | 마아즈, 인코오포레이티드 | 아르기나아제의 억제제와 그것의 치료적 적용 |
| EP3034509B1 (en) | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| JP6152167B2 (ja) * | 2012-04-18 | 2017-06-21 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としての環拘束性類似体 |
| PL410665A1 (pl) * | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EA201890113A1 (ru) * | 2015-06-23 | 2018-07-31 | Калитера Байосайенсиз, Инк. | Композиции и способы ингибирования активности аргиназы |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR TREATING CANCER BY MODULATING AN IMMUNE REACTION AGAINST CANCER |
| EP3538111B1 (en) * | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| EP3810615A4 (en) | 2018-06-20 | 2022-03-30 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
-
2019
- 2019-11-15 JP JP2021526441A patent/JP7461350B2/ja active Active
- 2019-11-15 EP EP19884624.8A patent/EP3880685A4/en active Pending
- 2019-11-15 AU AU2019379808A patent/AU2019379808C1/en active Active
- 2019-11-15 AR ARP190103373A patent/AR117102A1/es unknown
- 2019-11-15 TW TW108141665A patent/TWI828800B/zh active
- 2019-11-15 WO PCT/US2019/061657 patent/WO2020102646A2/en active Application Filing
- 2019-11-15 KR KR1020217018476A patent/KR20210108954A/ko not_active Application Discontinuation
- 2019-11-15 US US17/294,353 patent/US20220016143A1/en active Pending
- 2019-11-15 UY UY0001038476A patent/UY38476A/es unknown
- 2019-11-15 CA CA3120196A patent/CA3120196A1/en active Pending
- 2019-11-15 CN CN201980089420.2A patent/CN113382998A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529500A5 (ru) | ||
| JP2020519664A5 (ru) | ||
| JP2019535720A5 (ru) | ||
| JPWO2020102646A5 (ru) | ||
| IL295569A (en) | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha | |
| JP2010539095A5 (ru) | ||
| Hall et al. | Synthesis and structure–activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein | |
| ES2929283T3 (es) | Moduladores del receptor de relaxina 1 | |
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| JP2017525753A5 (ru) | ||
| KR20180017013A (ko) | K-Ras 조절제 | |
| JP2017538678A5 (ru) | ||
| JP2017538677A5 (ru) | ||
| JP2016053042A5 (ru) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| JP2016534134A5 (ru) | ||
| JP2014503567A5 (ru) | ||
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| RU2018128334A (ru) | Ингибиторы индоламин-2,3-диоксигеназы (ido) | |
| KR20170049604A (ko) | Bub1 억제제로서의 벤질 치환된 인다졸 | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2013056930A5 (ru) | ||
| JP2014524441A5 (ru) | ||
| RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
| JP2010522194A5 (ru) |